How have GNMSF shares performed in 2024?

Genmab A/S's stock was trading at $315.6999 at the start of the year. Since then, GNMSF stock has decreased by 8.0% and is now trading at $290.38. View the best growth stocks for 2024 here .

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings results on Wednesday, February, 14th. The company reported $3.63 earnings per share (EPS) for the quarter. The company earned $675.29 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 18.06% and a net margin of 26.50%.

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free GNMSF Stock Alerts

$284.55

-5.83 (-2.01%)

(As of 04:09 PM ET)

Compare

Today's Range: $283.30
▼
$288.30
50-Day Range: $262.26
▼
$313.00
52-Week Range: $262.00
▼
$426.50

Volume: 241 shs
Average Volume: 962 shs
Market Capitalization: N/A

P/E Ratio: 29.55
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Genmab A/S alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Genmab A/S Stock (OTCMKTS:GNMSF)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GNMSF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNMSF Stock News Headlines

April 16, 2024 | seekingalpha.com

Genmab Acquires A Missing Piece For Its Pipeline

April 16, 2024 | markets.businessinsider.com

Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 12, 2024 | americanbankingnews.com

Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $304.41

April 9, 2024 | markets.businessinsider.com

Truist Financial Keeps Their Buy Rating on Genmab (GMAB)

April 8, 2024 | benzinga.com

ProfoundBio discovers the joys of having a wealthy owner

March 17, 2024 | finance.yahoo.com

30 Biggest Biotechnology Companies in the World

March 13, 2024 | finance.yahoo.com

Passing of Genmab A/S’ Annual General Meeting

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

February 21, 2024 | seekingalpha.com

Genmab: Recent Updates Support The Growth Narrative

February 20, 2024 | markets.businessinsider.com

4 Analysts Assess Genmab: What You Need To Know

February 15, 2024 | msn.com

Genmab A/S’ New Regulation Risk – A Cause for Worry?

February 15, 2024 | finance.yahoo.com

Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript

February 15, 2024 | finance.yahoo.com

Notice to Convene the Annual General Meeting of Genmab A/S

February 14, 2024 | finance.yahoo.com

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

February 14, 2024 | finance.yahoo.com

Genmab: Growth Is Still a Better Choice

February 2, 2024 | finance.yahoo.com

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

January 29, 2024 | markets.businessinsider.com

Cracking The Code: Understanding Analyst Reviews For Genmab

January 25, 2024 | finance.yahoo.com

Grant of Restricted Stock Units and Warrants to Employees in Genmab

January 22, 2024 | finance.yahoo.com

Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

December 7, 2023 | finance.yahoo.com

HRMY or GMAB: Which Is the Better Value Stock Right Now?

November 8, 2023 | finance.yahoo.com

Genmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript

November 7, 2023 | msn.com

Genmab reports 9M results

November 7, 2023 | finance.yahoo.com

Genmab Announces Financial Results for the First Nine Months of 2023

November 2, 2023 | finance.yahoo.com

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

October 23, 2023 | msn.com

Genmab and Seagen report positive data from Phase III TIVDAK trial

October 23, 2023 | msn.com

Seagen, Genmab update Phase 3 data for uterine cancer therapy

See More Headlines

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:GNMSF
CUSIP: N/A
CIK: 1434265
Web: www.genmab.com
Phone: (457) 020-2728
Fax: 45-7020-2729
Employees: 2,204
Year Founded: 1999

Profitability

EPS (Most Recent Fiscal Year): $9.63
Trailing P/E Ratio: 30.15
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $631.91 million
Net Margins: 26.50%
Pretax Margin: 34.22%
Return on Equity: 18.06%
Return on Assets: 16.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.34
Quick Ratio: 13.32

Sales & Book Value

Annual Sales: $2.39 billion
Price / Sales: N/A
Cash Flow: $13.17 per share
Price / Cash Flow: 22.05
Book Value: $59.44 per share
Price / Book: 4.89

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.01

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
Co-Founder, President & CEO
Comp: $2.88M
Mr. Anthony Pagano (Age 46)
Executive VP & CFO
Comp: $1.02M
Ms. Birgitte Stephensen M.Sc. (Age 63)
Executive VP & Chief Legal Officer
Comp: $632.67k
Dr. Martine J. van Vugt Ph.D. (Age 53)
Executive VP & Chief Strategy Officer
Comp: $690.19k
Mr. Martin Schultz (Age 48)
Senior Director of Clinical Operations & Non-Independent Director
Comp: $115.03k
Dr. Tahamtan Ahmadi (Age 51)
Executive VP, Chief Medical Officer & Head of Experimental Medicines
Comp: $1.11M
Dr. Mijke Zachariasse Ph.D. (Age 50)
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Comp: $158.17k
Mr. Takahiro Hamatani (Age 49)
Senior Director of Finance Japan & Non-Independent Director
Comp: $115.03k
Mr. Anthony Mancini (Age 53)
Executive VP & COO
Comp: $1.09M
Mr. Andrew Carlsen
Senior Director, VP & Head of Investor Relations

Key Competitors

View All Competitors

GNMSF Stock Analysis - Frequently Asked Questions

How have GNMSF shares performed in 2024?: Genmab A/S's stock was trading at $315.6999 at the start of the year. Since then, GNMSF stock has decreased by 8.0% and is now trading at $290.38.
View the best growth stocks for 2024 here.
How were Genmab A/S's earnings last quarter?: Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings results on Wednesday, February, 14th. The company reported $3.63 earnings per share (EPS) for the quarter. The company earned $675.29 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 18.06% and a net margin of 26.50%.
How do I buy shares of Genmab A/S?: Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNMSF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial